Table 1:
Baseline Characteristics of Patients with Resected PDAC at Moffitt Cancer Center Between 2008 and 2015 by SED
| Low SED (n=117) | Moderate SED (n=101) | High SED (n=71) | Overall p | T rend p | |
|---|---|---|---|---|---|
| Age | 68.0 [64.0; 76.0] | 68.0 [61.0; 75.0] | 68.0 [61.0; 72.5] | 0.465 | 0.220 |
| Age (binary) | 0.639 | 0.361 | |||
| <70 | 66 (56.4%) | 59 (58.4%) | 45 (63.4%) | ||
| ≥70 | 51 (43.6%) | 42 (41.6%) | 26 (36.6%) | ||
| Sex | 0.203 | 0.124 | |||
| Female | 54 (46.2%) | 46 (45.5%) | 24 (33.8%) | ||
| Male | 63 (53.8%) | 55 (54.5%) | 47 (66.2%) | ||
| Race | 0.748 | 0.184 | |||
| White | 110 (94.0%) | 91 (90.1%) | 63 (88.7%) | ||
| Black | 4 (3.42%) | 5 (4.95%) | 4 (5.63%) | ||
| Other / unknown | 3 (2.56%) | 5 (4.95%) | 4 (5.63%) | ||
| Insurance | 0.237 | 0.083 | |||
| Private | 41 (35.0%) | 25 (24.8%) | 19 (26.8%) | ||
| Government with private supplement | 46 (39.3%) | 48 (47.5%) | 26 (36.6%) | ||
| Government | 30 (25.6%) | 28 (27.7%) | 26 (36.6%) | ||
| Distance from Moffitt (miles) | 56.5 [24.4; 128] | 48.9 [20.1; 97.3] | 54.8 [33.2; 104] | 0.062 | 0.460 |
| Distance from Moffitt (binary) | 0.195 | 0.412 | |||
| < 85 miles | 71 (60.7%) | 73 (72.3%) | 46 (64.8%) | ||
| ≥ 85 miles | 46 (39.3%) | 28 (27.7%) | 25 (35.2%) | ||
| Charlson comorbidity index | 0.355 | 0.339 | |||
| ≤3 | 31 (26.5%) | 23 (22.8%) | 13 (18.3%) | ||
| 4–5 | 60 (51.3%) | 47 (46.5%) | 42 (59.2%) | ||
| ≥6 | 26 (22.2%) | 31 (30.7%) | 16 (22.5%) | ||
| BMI | 26.0 [23.7; 28.8] | 25.8 [23.5; 29.6] | 27.1 [23.1; 31.8] | 0.399 | 0.281 |
| Diabetes mellitus | 0.193 | 0.102 | |||
| No | 91 (77.8%) | 69 (68.3%) | 48 (67.6%) | ||
| Yes | 26 (22.2%) | 32 (31.7%) | 23 (32.4%) | ||
| Preoperative biliary stent | 0.433 | 0.335 | |||
| No | 55 (47.0%) | 39 (38.6%) | 29 (40.8%) | ||
| Yes | 62 (53.0%) | 62 (61.4%) | 42 (59.2%) | ||
| Preoperative resectability | 0.550 | 0.649 | |||
| Resectable | 80 (68.4%) | 62 (61.4%) | 47 (66.2%) | ||
| Borderline resectable | 37 (31.6%) | 39 (38.6%) | 24 (33.8%) | ||
| Neoadjuvant therapy | 0.456 | 0.632 | |||
| No | 80 (68.4%) | 61 (60.4%) | 47 (66.2%) | ||
| Yes | 37 (31.6%) | 40 (39.6%) | 24 (33.8%) | ||
| ASA class | 0.144 | 0.197 | |||
| 2 | 57 (48.7%) | 36 (35.6%) | 29 (40.8%) | ||
| 3 | 60 (51.3%) | 65 (64.4%) | 42 (59.2%) | ||
| Surgery | 0.590 | 0.336 | |||
| Whipple/total pancreatectomy | 90 (76.9%) | 79 (78.2%) | 59 (83.1%) | ||
| Distal pancreatectomy/splenectomy | 27 (23.1%) | 22 (21.8%) | 12 (16.9%) | ||
| Vascular Reconstruction | 0.226 | 0.130 | |||
| No | 105 (89.7%) | 90 (89.1%) | 58 (81.7%) | ||
| Venous | 12 (10.3%) | 11 (10.9%) | 13 (18.3%) | ||
| Estimated blood loss | 300 [200;525] | 300 [200;500] | 300 [150;500] | 0.551 | 0.830 |
| Operative Time (hours) | 6.33 [4.67;8.00] | 6.92 [5.03;8.47] | 7.32 [5.46;9.24] | 0.074 | 0.022 |
| Pathologic tumor stage | 0.202 | 0.106 | |||
| CR or in situ | 11 (9.40%) | 9 (8.91%) | 1 (1.41%) | ||
| T1 | 9 (7.69%) | 6 (5.94%) | 9 (12.7%) | ||
| T2 | 59 (50.4%) | 47 (46.5%) | 31 (43.7%) | ||
| T3 | 38 (32.5%) | 39 (38.6%) | 30 (42.3%) | ||
| Positive lymph nodes | 0.252 | 0.111 | |||
| N0 (0) | 51 (43.6%) | 48 (47.5%) | 24 (33.8%) | ||
| N1 (1–3) | 47 (40.2%) | 37 (36.6%) | 28 (39.4%) | ||
| N2 (4+) | 19 (16.2%) | 16 (15.8%) | 19 (26.8%) | ||
| Margin Status | 0.066 | 0.304 | |||
| R0 | 100 (85.5%) | 96 (95.0%) | 63 (88.7%) | ||
| R1 | 17 (14.5%) | 5 (4.95%) | 8 (11.3%) | ||
| Lymphovascular invasion | 0.191 | 0.229 | |||
| No | 29 (25.0%) | 36 (36.4%) | 22 (31.9%) | ||
| Yes | 87 (75.0%) | 63 (63.6%) | 47 (68.1%) | ||
| Perineural invasion | 0.143 | 0.208 | |||
| No | 15 (12.9%) | 23 (23.2%) | 13 (18.8%) | ||
| Yes | 101 (87.1%) | 76 (76.8%) | 56 (81.2%) | ||
| Clavien complication (grade 3/4) | 0.412 | 0.920 | |||
| No | 102 (87.2%) | 83 (82.2%) | 63 (88.7%) | ||
| Yes | 15 (12.8%) | 18 (17.8%) | 8 (11.3%) | ||
| Pancreatic fistula (grade B/C) | 0.891 | 0.639 | |||
| None | 101 (86.3%) | 88 (87.1%) | 63 (88.7%) | ||
| Yes | 16 (13.7%) | 13 (12.9%) | 8 (11.3%) | ||
| Length of stay | 10.0 [8.00; 13.0] | 11.0 [9.00; 14.0] | 10.0 [8.00; 15.0] | 0.361 | 0.230 |
| Readmission by 90 days | 0.082 | 0.406 | |||
| No | 98 (83.8%) | 78 (77.2%) | 64 (90.1%) | ||
| Yes | 19 (16.2%) | 23 (22.8%) | 7 (9.86%) | ||
| Initiated adjuvant therapy | 0.504 | 0.958 | |||
| No, failed to initiate | 19 (16.7%) | 22 (22.0%) | 11 (15.9%) | ||
| Yes, initiated | 95 (83.3%) | 78 (78.0%) | 58 (84.1%) | ||
| Completed adjuvant therapy | 0.636 | 0.983 | |||
| No, failed to complete | 37 (32.7%) | 38 (38.0%) | 22 (31.9%) | ||
| Yes, completed | 76 (67.3%) | 62 (62.0%) | 47 (68.1%) | ||
| Overall survival | |||||
| Alive | 29 (24.8) | 27 (26.7) | 18 (25.4) | 0.946 | 0.705 |
| Dead | 88 (75.2) | 74 (73.3) | 53 (74.6) |